Rare and Complex Urology: Clinical Overview of ERN eUROGEN

Emilio Sacco, Loes Oomen, Erik Leijte, Darren E. Shilhan, Michelle Battye, David Waltregny, Frank Van Der Aa, Anne-Françoise Spinoit, Wolfgang H. Rösch, Eberhard Schmiedeke, Margit Fisch, Stefanie Märzheuser, Jan-Hendrik Gosemann, Jochen Hubertus, Yazan Rawashdeh, Jorgen Thorup, Yves Heloury, Ernesto Leva, Mariangela Mancini, Pietro BagolanGilvydas Verkauskas, Wout Feitz, Cornelius Sloots, Piotr Czauderna, Maria Mauricio, Gundela Holmdahl, Kate Abrahamsson, Kay Thomas, Linda Cardozo, Christopher Chapple, Vijay Sangar, Tamsin Greenwell, Nick Watkin, Anna Bujons Tur, Jose Lozano Ortega, Maria Begoña Pérez-Valderrama, Jose Gutierrez Baños, Luis Garcia Aparicio, Manuel Lopez, Javier Romero Otero, Pedro Lopez Pereira, Felipe Herranz Amo, Josef Oswald, Valts Abols, Ana Frobe, Maria Judit Molnar, Martine Goergen, Miriam Dalmas, Luca Lovrecic, Wout F.J. Feitz

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background: In 2017, the European Commission launched 24 European Reference Networks (ERNs). ERN eUROGEN is the network for urorectogenital diseases and complex conditions, and started with 29 full member healthcare providers (HCPs) in 11 countries. It then covered 19 different disease areas distributed over three workstreams (WSs). Objective: To provide an overview and identify challenges in data collection at European level of the ERN eUROGEN patient population treated by HCPs in the network. Design, setting, and participants: A retrospective cohort study was conducted of the 29 HCPs who were full members between 2013 and 2019. Outcome measurements and statistical analysis: Data were extracted from the original HCP applications and the ERN continuous monitoring system. Patient volumes, new patient numbers, and procedures were compared between different WSs, countries, and HCPs. Discrepancies between monitoring and application data were identified. Results and limitations: Between 2013 and 2019, 122 040 patients required long-term care within the 29 HCPs. The volume of patients treated and procedures undertaken per year increased over time. Large discrepancies were found between patient numbers contained in the application forms and those reported in the continuous monitoring system (0–1357% deviation). Conclusions: Patient numbers and procedures increased across ERN eUROGEN HCPs. Reliable data extraction appeared challenging, illustrated by the patient volume discrepancies between application forms and the continuous monitoring data. Improved disease definitions, re-evaluation of affiliated HCPs, and valid data extraction are needed for future improvements. Patient summary: We analysed the patient population with rare urorectogenital diseases or complex conditions within the ERN eUROGEN network between 2013 and 2019. Clinical activity was found to increase, but differences in patient numbers were evident between healthcare providers. In order to acquire valid patient numbers, both improved definitions of diagnostic codes and greater insight into the data-gathering process are required. For patients with a rare or complex urological anomaly and their care takers, ERN eUROGEN aims to improve knowledge exchange and expertise sharing, to optimise care pathways and innovate cure potential for all rare urorectogenital diseases and complex conditions in the European Union. The data show that ERN eUROGEN's healthcare providers and expert multidisciplinary teams are treating an increasing number of patients and performing an increasing number of complex surgical procedures.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaEuropean Urology
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Collaboration
  • Complex conditions
  • European Reference Network
  • Rare
  • Rare diseases
  • Urology
  • eUROGEN

Fingerprint

Entra nei temi di ricerca di 'Rare and Complex Urology: Clinical Overview of ERN eUROGEN'. Insieme formano una fingerprint unica.

Cita questo